证券代码：300981 证券简称：中红医疗 公告编号：2024-061 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 变更注册的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 上述医疗器械注册证的相关变更，是在原有注册证的基础上根据相关要求进 行相应的变更，延续和丰富了公司及子公司在一次性使用输液器（带针）领域的 产品品类，有利于进一步提高市场应用拓展能力，进而增强公司及子公司的综合 竞争力。 上述产品实际销售情况取决于未来市场的推广效果，产品销售及利润贡献具 有不确定性，目前尚无法预测上述产品对公司未来业绩的影响，敬请投资者注意 防范投资风险。 三、备查文件 特此公告。 中红普林医疗用品股份有限公司 董事会 二〇二四年十月八日 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司（以下简称"科伦医械"）于近期取得国家药品监督管理局颁 发的《医疗器械变更注册（备案）文件》。根据 GB 8368-2018 的相关要求，科伦 医械对原有注册证在结构及组成、型号规格、产品技术要求方面进行了变更 ...

[Table_MainInfo] 公司研究/医药与健康护理 证券研究报告 中红医疗（300981）公司研究报告 2024 年 09 月 29 日 [Table_InvestInfo] 投资评级 优于大市 首次 覆盖 | --- | --- | |---------------------------------------------------|------------| | 股票数据 | | | 09 [ Table_StockInfo 月 27 日收盘价（元） ] | 11.45 | | 52 周股价波动（元） | 8.31-17.87 | | 总股本 / 流通 A 股（百万股） | 390/357 | | 总市值 / 流通市值（百万元） 相关研究 | 4466/4093 | 市场表现 [Table_QuoteInfo] -40.05% -30.05% -20.05% -10.05% -0.05% 2023/10 2024/1 2024/4 2024/7 中红医疗 海通综指 | --- | --- | --- | --- | |-------------------------------------- ...

证券代码：300981 证券简称：中红医疗 公告编号：2024-060 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司参与多个集中 带量采购项目拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期参加了甘肃省兰州市市 际联盟普通医用耗材集中带量采购和河北省一次性使用导尿包等 7 种医用耗材 带量联动采购项目的投标工作。根据甘肃省公共资源交易中心和河北省医用药品 器械集中采购中心官网拟中选结果相关公告显示，科伦医械部分产品拟中选上述 集中带量采购项目。现将相关情况公告如下： 三、风险提示 本次拟中选产品相关采购合同尚未签订，后续事项及对公司的影响程度具有 不确定性。公司将密切关注该事项的进展情况并及时履行信息披露义务，敬请广 大投资者谨慎决策，注意投资风险。 特此公告。 中红普林医疗用品股份有限公司 二、对公司的影响 科伦医械为公司安全输注事业部主要子公司，科伦医械一次性使用人体静脉 项目采购品种 注册 分类 产品 ...

中红普林医疗用品股份有限公司 2024 年 8 月 30 日投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------------|--------|--------------------------------|----------|--------------------------------------------------------|--------------| | | | | | | | | | □ | 特定对象调研 | □ | 分析师会议 | | | | □ | 媒体采访 | □ | 业绩说明会 | | | 投资者关系活动 | □ | 新闻发布会 | □ | 路演活动 | | | 类别 | □ | 现场参观 | | | | | | √ | 其他 2024 | | 年半年度报告电话会 | | | | | | | 本次电话会议参会机构如下（排名不分先后）： | | | | | 天风证券 | 中邮证券 | 东吴证券 | 兴业证券 | | | | 国盛证券 | 海通证券 | 中信证券 | 中信建投证券 | | ...

证券代码：300981 证券简称：中红医疗 公告编号：2024-059 中红普林医疗用品股份有限公司 关于开立募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）于 2023 年 12 月 5 日 召开了第三届董事会第二十六次会议和第三届监事会第二十次会议，审议通过了 《关于 2024 年度拟使用暂时闲置超募资金及其利息进行现金管理暨关联交易的 议案》，同意公司 2024 年度在不影响募集资金投资项目建设和公司正常运营的 情况下，对暂时闲置超募资金及其利息在确定投资计划前进行现金管理，以增加 公司收益；使用闲置超募资金及其利息的额度不超过 9 亿元，其中涉及与世纪证 券有限责任公司关联交易的额度不超过 3 亿元，单个产品期限不超过十二个月， 资金可循环滚动使用，闲置募集资金现金管理到期后将及时归还至募集资金专户， 进行现金管理的投资产品包括但不限于结构性存款、定期存款、大额存单、收益 凭证和国债逆回购等安全性高、流动性好的保本型理财产品；董事会提请股东大 会授权董事长、总经理或其授 ...

| | 中红普林（北京）医 疗用品高新技术研究 | 全资子公司 | 其他应收款 | 67.77 | 62.03 | | 129.80 | 日常经营资金 需求 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 院有限公司 | | | | | | | | | | | 中红医疗用品（海 | 全资子公司 | 其他应收款 | 1,942.65 | 2,560.00 | 1,570.00 | 2,932.65 | 日常经营资金 | 非经营性往来 | | | 南）有限公司 | | | | | | | 需求 | | | | 中红医疗用品（上 海）有限公司 | 全资子公司 | 其他应收款 | 74.97 | 249.00 | 214.32 | 109.65 | 日常经营资金 需求 | 非经营性往来 | | | 广西中红医疗用品有 限公司 | 全资子公司 | 其他应收款 | 1,335.00 | | | 1,335.00 | 日常经营资金 需求 | 非经营性往来 | | | 深圳迈德瑞纳生物科 | 控股子公司 | 其他应收款 ...

海通证券股份有限公司关于中红普林医疗用品股份有限公司 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1、信息披露 | 无 | 不适用 | | 2、公司内部制度的建立和执行 | 无 | 不适用 | | 3、"三会"运作 | 无 | 不适用 | | 4、控股股东及实际控制人变动 | 无 | 不适用 | | 5、募集资金存放及使用 | 无 | 不适用 | | 6、关联交易 | 无 | 不适用 | | 7、对外担保 | 无 | 不适用 | | 8、收购、出售资产 | 无 | 不适用 | | 9、其他业务类别重要事项（包括对外投资、风险投 资、委托理财、财务资助、套期保值等） | 无 | 不适用 | | 10、发行人或者其聘请的中介机构配合保荐工作的情 况 | 无 | 不适用 | | 11、其他（包括经营环境、业务发展、财务状况、管 | | | | 理状况、核心技术等方面的重大变化情况） | 无 | 不适用 | 三、公司及股东承诺事项履行情况 2 | 公司及股东承诺事项 | 是否履行承诺 | 未履行承诺的原因及解 | | --- | --- | --- | | | | 决措施 ...

证券代码：300981 证券简称：中红医疗 公告编号：2024-054 中红普林医疗用品股份有限公司 第四届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2. 审议通过《关于 2024 年半年度计提减值准备的议案》 公司监事会认为：公司本次计提减值准备符合《企业会计准则》等相关规定 和公司实际情况。本次计提减值准备后，能够更加公允地反映公司经营状况，履 行的决策程序符合相关法律法规及《公司章程》的规定，不存在损害公司及全体 投资者利益的情形。 二、会议审议情况 1. 审议通过《关于<2024 年半年度报告及其摘要>的议案》 公司监事会认为：公司编制的《2024 年半年度报告》和《2024 年半年度报 告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 一、会议召开情况 表决结果为：同意 3 票，反对 0 票，弃权 0 票。 中红普林医疗用品股份有限公司（以下简称"公司"）第四届监事会第二次 （定期）会议于 2024 年 8 月 29 日以 ...

Financial Performance - The company's operating revenue for the reporting period reached ¥1,148,451,821.02, representing a 14.97% increase compared to ¥998,882,650.75 in the same period last year[13]. - The net profit attributable to shareholders was ¥32,529,868.67, a significant turnaround from a loss of ¥4,942,596.19 in the previous year, marking a 758.15% increase[13]. - The net cash flow from operating activities was negative at ¥84,900,776.67, a decline of 318.91% compared to a positive cash flow of ¥38,783,180.75 in the same period last year[13]. - Basic earnings per share improved to ¥0.0836 from a loss of ¥0.0127, reflecting a 758.27% increase[13]. - Total assets at the end of the reporting period amounted to ¥7,461,891,884.23, up 5.74% from ¥7,056,973,990.05 at the end of the previous year[13]. - The net assets attributable to shareholders decreased by 2.96%, totaling ¥5,597,112,677.39 compared to ¥5,768,086,190.12 at the end of the previous year[13]. - The company reported non-recurring gains and losses totaling ¥36,802,014.42 for the period[17]. - The company experienced a 90.42% reduction in net profit after deducting non-recurring gains and losses, resulting in a loss of ¥4,272,145.75[13]. - The weighted average return on net assets was 0.56%, an increase of 0.64 percentage points from -0.08% in the previous year[13]. - The company’s cash and cash equivalents increased by 93.28%, reaching ¥274,118,589.65 compared to ¥141,826,253.83 in the previous year[62]. Market and Industry Insights - The global medical device market was valued at $489 billion in 2021 and is projected to grow at a CAGR of 5.5%, reaching over $580 billion by 2025 and approximately $719 billion by 2029[19]. - The disposable health protection gloves market is experiencing a significant recovery, with domestic manufacturers seeing an increase in quality orders due to rising health awareness and demand in emerging markets[23]. - The safe infusion product market is stable, with a significant share in low-value medical consumables, driven by the number of hospital admissions and supported by government policies favoring domestic medical supplies[25]. - The company is positioned to benefit from the increasing focus on high-quality medical services and the expansion of the medical device market in China, as indicated by recent government reports[19]. - The medical device industry is expected to expand due to increasing health awareness and rising consumption levels in emerging markets, providing greater market potential for the company's main products[45]. Product Development and Innovation - The company is involved in the research and development of new medical products, although specific details are not provided in the content[2]. - The company is enhancing its product offerings in the life support category, including infusion pumps and monitoring systems, to meet the growing demand for advanced medical solutions[20]. - The company has developed over 100 different types of condoms, meeting various market demands and achieving full-category production and sales[30]. - The company has invested 8 years in R&D to produce the first barrier condom in 2019, which combines the elasticity of natural latex with modified polyurethane[38]. - The company has established five research institutes and collaborates with various universities and research institutions for product development and registration[44]. Compliance and Risk Management - The company emphasizes the importance of risk awareness regarding future plans, which depend on various factors including international political environment and market supply-demand relationships[2]. - The company acknowledges the potential risks it faces and has outlined measures to address these risks in its management discussion[2]. - The company is committed to maintaining compliance with international standards such as ISO13485 for medical device quality management[6]. - The company has received various international certifications, including FDA and CE, and exports to over 80 countries, indicating strong global market presence[29]. - The company has established a derivative investment management system to control risks associated with foreign exchange derivatives, ensuring compliance and effective management[83]. Environmental Responsibility - The company strictly adheres to various environmental protection laws and standards, ensuring compliance with pollutant discharge requirements[101]. - The company has established wastewater treatment facilities that consistently meet discharge standards, with online monitoring systems in place[104]. - The total investment in environmental governance and protection by the company and its subsidiaries for the first half of 2024 was approximately 8 million yuan[105]. - The company has not experienced any environmental pollution incidents during the reporting period[104]. - The company emphasizes a sustainable development approach, focusing on reducing waste and carbon emissions while increasing efficiency and production[107]. Corporate Governance and Shareholder Engagement - The company has a commitment to transparency, with all board members present for the review of the half-year report[1]. - The company held its annual general meeting on May 16, 2024, with a participation rate of 71.71%[99]. - The company has actively engaged with investors through various communication channels to enhance shareholder participation[105]. - The company has established a stock repurchase plan to stabilize its stock price, with conditions based on the audited net asset value per share[111]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[118]. Financial Management and Investments - The company has a strong cash flow and low debt-to-asset ratio, providing a solid financial foundation for new business development, mergers and acquisitions, and R&D investments[58]. - The company has engaged in cash management of idle raised funds amounting to RMB 651,000,000.00, generating interest income and investment returns of RMB 10,776,150.93 during the reporting period[76]. - The company has not made significant progress in major non-equity investments during the reporting period[71]. - The company has not reported any overdue amounts or uncollected funds from entrusted financial management during the reporting period[81]. - The company plans to continue investing in mergers and acquisitions to explore new market segments and innovate product offerings[46].

中红普林医疗用品股份有限公司 2024 年半年度募集资金存放与实际使用情况专项报告 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》和《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》等 有关规定的要求，现将本公司 2024 年半年度募集资金存放与实际使用情况说明 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意中红普林医疗用品股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕758 号）同意注册，公司首次公开 发行人民币普通股（A 股）股票 41,670,000 股，每股面值 1.00 元，发行价为每 股人民币 48.59 元，募集资金总额为人民币 2,024,745,300.00 元，扣除发行费 用总额（不含增值税）人民币 128,288,946.26 元，实际募集资金净额为人民币 1,896,456,353.74 元。募集资金 1,917,800,968.44 元(含部分未划转发行费用) 已于 2021 年 4 月 2 ...